Skip to main content
Fig. 5 | The Journal of Headache and Pain

Fig. 5

From: Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials

Fig. 5

Proportion of patients achieving ≥ 50, ≥75 and 100 % reduction from baseline in monthly MSMD in CM study through (A) DBTP and (B) OLTP. The common odds ratios and p-values are obtained from a CMH test, stratified by stratification factors region and medication overuse status. P-values for pairwise comparisons are nominal p-values obtained from the CMH test using data including placebo and corresponding erenumab dose group only. CM, chronic migraine; CMH, Cochran-Mantel-Haenszel, MSMD, migraine-specific medication days; OLTP, open-label treatment phase; OR, odds ratio

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us